Gt biopharma presents preclinical data demonstrating novel b7h3+ tumor targeting gtb-5550 trike® driving nk cell activation and adcc against head and neck squamous cell carcinomas at aacr annual meeting 2022

- ongoing experiments will evaluate the functionality and efficacy of the b7h3 trike in vivo - future studies will also involve assessments of the b7h3 trike efficacy in the hnscc tumor microenvironment
GTBP Ratings Summary
GTBP Quant Ranking